Stock Analysis
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis
Xenon Pharmaceuticals Inc. (XENE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Xenon Pharmaceuticals Inc. (XENE) currently has an AIQ Score of 49/100, indicating a bearish setup. Quality is the strongest factor at 68/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
XENE at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $40.48 |
| AIQ Score | 49/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Buy |
| Market Cap | $4.04B |
| P/E Ratio (TTM) | -8.61 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.11 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.86 |
| Volume | 607.68K |
| 52-week range | $33.38-$72.66 |
| RSI 14 | 54.92 |
| 50-Day SMA | $41.13 |
| 200-Day SMA | $52.28 |
| Analyst Price Target | $67.86 |
| Next Earnings | Feb 25, 2027 |
XENEXenon Pharmaceuticals Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum33
- Value—
- Quality68
- Risk resilience49
- Sentiment—
XENE Stock Analysis Summary
Xenon Pharmaceuticals Inc. (XENE) currently has an AIQ Score of 49/100, indicating a bearish setup. Quality is the strongest factor at 68/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, XENE has AIQ Score of 49/100 with Quality base of 68/100 and fading Momentum at 33/100. Wait for component alignment before adding exposure.
Quality (68/100) leads while Momentum (33/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.26% stock move · XENE classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is XENE Bullish or Bearish Right Now?
XENE currently has a bearish overall setup. Quality is the strongest factor at 68/100, while Momentum is weakest at 33/100. The current evidence suggests a bearish setup.
- - Quality is supportive at 68/100.
- - Analyst target implies +67.63% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (27 vs 13).
- - Momentum is weak at 33/100.
- - Risk Resilience is weak at 49/100.
- - Price is -22.56% below its 200-day SMA.
Current Consensus
XENE's Technical Analysis Consensus is currently Buy, with 27 buy, 6 neutral, and 13 sell votes. XENE's 14-day RSI is 54.92, which places the stock in a neutral momentum range. XENE's beta is 0.86, indicating market sensitivity broadly in line with the market.
What Changed in XENE?
The largest recent change in XENE is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the XENE Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
XENE Decision Framework
Public evidence layers, setup checks, and risk context for Xenon Pharmaceuticals Inc..
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis
Xenon Pharmaceuticals Inc. has an AIQ Score of 49/100 in a Bearish regime. Quality is strongest at 68/100. Beta is 0.86, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | XENE is in a Bearish AIQ regime with score 49/100. |
| Signal Conflict | The primary conflict is that quality leads at 68/100 while momentum lags at 33/100. |
| Factor Evidence | Momentum 33/100 · Quality 68/100 · Risk 49/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 68/100.
Momentum is 33/100 and RSI (14) is 54.9.
XENE is in a Bearish regime at 49/100.
Risk factor is 49/100 with beta 0.86 and annual volatility 68.13%.
Current conflict: quality leads at 68/100 while momentum lags at 33/100.
XENE Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
XENE Fundamentals
XENE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
XENE Technical Analysis
XENE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
XENE Stock Catalysts
Track XENE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
XENE Dividend Analysis
XENE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
XENE Financial Data
XENE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
XENE Risk Analysis
XENE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
XENE Stock News
XENE stock news, market tone, recent headlines, and catalyst context.
XENE vs Biotechnology Peers
Current peer cohort: XENE · XERS · ZBIO · ZYME · ABCL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| XENE Current stock | 49/100 | — | 33/100 | 49/100 | 0.27 | 68.13% | Current |
| XERS Xeris Biopharma Holdings, Inc. | 78/100 | 68/100 | 98/100 | 55/100 | 1.67 | 56.97% | XENE vs XERS |
| ZBIO Zenas BioPharma, Inc. | 47/100 | 33/100 | 78/100 | 39/100 | 0.26 | 95.33% | XENE vs ZBIO |
| ZYME Zymeworks Inc. | 68/100 | 66/100 | 78/100 | 61/100 | 0.84 | 54.03% | XENE vs ZYME |
| ABCL AbCellera Biologics Inc. | 64/100 | 47/100 | 89/100 | 34/100 | 1.73 | 85.28% | XENE vs ABCL |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for XENE: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching XENE
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for XENE
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
XENE Stock FAQ
What is XENE stock price today?
Xenon Pharmaceuticals Inc.'s current stock price is $40.48. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is XENE bullish or bearish right now?
XENE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is XENE's market cap?
XENE's market cap is $4.04B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is XENE's current P/E ratio?
XENE's current P/E ratio is -8.61 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is XENE's RSI?
XENE's 14-day RSI is 54.92 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is XENE above its 50-day and 200-day moving averages?
XENE is -1.58% from its 50-day SMA and -22.56% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is XENE's next earnings date?
XENE's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does XENE pay a dividend?
XENE's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.